Generex Biotechnology Corporation, a leader in the area of buccal drug delivery, has announced that it was actively engaged in the research and development of GlucoSprayT, a proprietary oral glucose spray formulation, to be delivered by way of the Company's proprietary RapidMistT device.

Generex's preliminary research and development efforts have demonstrated that glucose in the Company's proprietary formulation (GlucoSprayT), can be delivered into the body very rapidly through the buccual mucosa in the mouth using the Company's proprietary RapidMistT device, with glucose appearing in the blood within five minutes. As a result, precious minutes of relief should be provided to the brain thereby preventing some comas and ameliorating symptoms earlier. GlucoSprayT could be conceivably administered to a comatose patient.

Generex also has entered into an agreement with PharmaBrand S.A., a leading distributor of pharmaceutical products in Central & Latin America, for the marketing and distribution of GlucoSprayT in Ecuador following receipt of speedy governmental approvals.